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Abstract
Purpose To register all cases of urothelial cancer and renal cell carcinoma (RCC) in Norway during 1999–2018 to obtain 
the contemporary incidence of UTUC and UTUC incidence relative to other urothelial cancers and RCC. Further to analyse 
possible changes over time regarding UTUC incidence, UTUC patient characteristics, tumour characteristics and survival.
Methods 3502 cases registered with ICD code C65 and C66 during 1999–2018 at the Norwegian cancer registry were 
entered into a database. After a selection process 3096 cases were included in the study. The crude incidences of UTUC were 
calculated for each year adjusting for the corresponding population data. Age-standardized rates adjusting to the European 
standard population (2013) were calculated. Comparisons were made with other cases of urothelial cancer and RCC. For 
changes over time, the material was split into 5-year periods. Regression analysis was used to calculate yearly changes and 
for assessing statistical significance. Survival outcomes were calculated using the Kaplan–Meier method.
Results The overall age-standardized incidence rate was 3.88, increasing from 3.21 to 4.70 from first to last 5-year periods. 
The increase affected all ages except those < 60 years of age, and were observed regardless of gender or anatomical location. 
UTUC constituted 11.8% of all urothelial cancers, increasing from 9.9 to 12.8%. Mean patient age at diagnosis increased 
from 71.5 to 73.4 years. The 5-years Cancer-specific survival improved from 57.4 to 65.4%.
Conclusion The incidence of UTUC was higher than expected and increasing. Patient age at diagnosis was increasing.
Keywords Upper tract urothelial carcinoma · Epidemiology · Incidence · Registry data · Population based study
Introduction
Compared to urothelial cancer of the bladder (BC), upper 
tract urothelial carcinoma (UTUC) is relatively uncom-
mon. The incidence is typically referred to be 1–2:100.000 
per year or 5–10% of all urothelial carcinomas. Urothelial 
cancer in the kidney pelvis has been referred to constitute 
7% of all renal tumours. As a source of these numbers, the 
yearly publication from the American Cancer Society is 
often quoted [1]. In the yearly publication from the Nor-
wegian national database at the Cancer Registry of Norway 
(NCR) all new cancer cases of UTUC are merged with cases 
of the much more common BC and cancer of the urethra 
[2]. Specific contemporary data regarding the incidence of 
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UTUC and changes over time is limited. Some authors have 
reported an increasing incidence of UTUC [3, 4], while oth-
ers have reported a stable incidence, or even a decline [5, 
6]. To our knowledge, currently published papers on this 
topic do not include patient cohorts after 2011. Basic epide-
miological knowledge is essential in the planning of diag-
nostic evaluations, treatment and research of a particular 
disease. We, therefore, decided to gather and analyse avail-
able data regarding UTUC from the NCR in Norway during 
1999–2018. We formulated the following aims for the study.
Primary objective
To register all cases of UTUC together with all other cases 
of urothelial cancer and renal cell carcinoma (RCC) in Nor-
way during 1999–2018 to obtain the contemporary incidence 
of UTUC in Norway together with UTUC incidence relative 
to other urothelial cancers and RCC.
Secondary objective
To look for and analyse possible changes over time regard-
ing UTUC incidence, patient and tumour characteristics and 
survival outcomes.
Material and method
All patients classified with the International Classification 
of Diseases tenth revision [7] (ICD-10) diagnosis code 
C65 (cancer in the kidney pelvis) and C66 (cancer in the 
ureter) registered during 1999–2018 were extracted from 
the main database at NCR. A dataset of 3502 cases was 
obtained. For comparison, a similar extraction was made 
for renal cell carcinoma (RCC, C64, n = 14,500), BC (C67, 
n = 27,427 and Urethral cancer (C68, n = 440). The data-
base included information about patient sex, age at diag-
nosis, date of birth, histopathological data, clinical data 
(cancer report, death report including the cause of death 
etc.), treatment and current status (deceased or alive). The 
data from the NCR include nodal status and metastasis at 
diagnosis if present, but complete data on pathological 
or clinical tumour stage is not available. As a substitute, 
the tumours are coded as invasive (pT2 +) or non-invasive 
(pTa/T1). This classification is available for pure urothe-
lial carcinomas only (see Table 1). The inclusion/exclu-
sion process is illustrated in supplementary Fig. 1. In the 
case of diagnostic uncertainty, the cases were examined 
manually together with NCR personnel to clarify the basis 
of the diagnosis code and consider if the cases could be 
included or not. Of 1026 uncertain UTUC cases, 305 were 
excluded, typically where the diagnosis code was based 
on atypical cells by cytology or biopsy, when the tumour 
was coded wrong and was benign (i.e. benign papilloma) 
or when there was doubt whether the cells were benign 
or malignant. In 29 cases, the diagnosis code was based 
on very sparse information, i.e. only a death report or a 
clinical report based on autopsy or clinical examination, 
and these were excluded. In addition, 72 cases of pure 
non-urothelial cancers (i.e. squamous cell carcinoma or 
adenocarcinoma) were excluded. All cases of pure urothe-
lial carcinoma and cases of urothelial carcinoma with 
divergent differentiation were included. A comprehensive 
list of included and excluded cases is shown in Table 1. 
In all, 3096 cases in 2818 patients were included in the 
final analysis. More than one case of UTUC on the same 
patient was uncommon and only registered if data sug-
gested a truly new tumour, i.e. considerable time between 
cases or a new tumour on the opposite side. All analyses 
were performed according to number of cases, not num-
ber of patients. Of all 3096 cases, 2969 (95.9%) were 
verified with histopathological examination of a surgical 
specimen (n = 2327, 75.2%), biopsy (n = 576, 18.6%) or 
cytology (n = 66, 2.1%). In the remaining 127 (4.1%), the 
basis was a clinical report using radiological examination, 
endoscopic procedure or radiation therapy data as sources 
for the diagnosis codes. Similar inclusion and exclusion 
Table 1  Description of included and excluded cases in the study
a Percentages given as % of both included and excluded cases and 
might differ from % in manuscript
Tumour characteristics n %a
All cases 3502 100
Included 3096 88.4
 Pure urothelial carcinoma 2856 81.6
 Urothelial carcinoma with divergent dif-
ferentiation
45 1.3
 Carcinoma in situ 68 1.9
 No histopathological verification 127 3.6
Excluded 406 11.6
 Other malignant tumour 72 2.1




  Neuroendocrine tumour 4 0.1
  Other 1  < 0.1
 Benign tumour/uncertain 305 8.8
  Urothelial Atypia/dysplasia etc 288 8.2
  Benign tumour 17 0.5
 Limited data available 29 0.8
  Death certificate only 11 0.3
  Autopsy only 8 0.2
  Clinical examination only 10 0.3
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processes were performed regarding BC, urethral cancer 
and RCC resulting in 24,467 included cases of BC, 13,619 
with RCC and 287 with urethral cancer.
For incidence rates, crude rates were calculated using 
population data in Norway corresponding to each year 
from 1999 to 2018. To adjust for demographic differences 
between the Norwegian and other populations, age-standard-
ized rates (ASR) according to the European standard popula-
tion published in 2013 were calculated [8]. ASRs adjusted to 
other available standard populations were also calculated for 
comparison (see supplementary Table 1 and 2).
Statistical analysis
For the purpose of analysing changes over time, the mate-
rial was split into 5-year periods (1999–2003, 2004–2008, 
2009–2013 and 2014–2018). The relative proportion of 
UTUC cases compared to all urothelial cancer cases and 
pelvic urothelial tumour cases compared to RCC cases 
were calculated for each 5-year periods. Analyses regarding 
potential changes in patient age, gender distribution, location 
of the tumour and tumour features were performed in the 
same manner. For further analyses of changes over time, the 
estimated average percentage changes (EAPC) for incidence 
rates were calculated and linear regression analyses were 
used to calculate yearly changes and for assessing statis-
tical significance. Survival analyses included both overall 
survival (OS) and cancer-specific survival (CSS) and were 
performed using the Kaplan–Meier method. Categorical data 
were analysed using the Chi-square method. Data were ana-
lysed using IBM® SPSS® Statistics v. 26. P values less than 
0.05 were considered statistically significant.
Results
The developments in crude rates and ASRs of UTUC dur-
ing the study period are illustrated in Fig. 1. Specific ASR 
regarding UTUC in the kidney pelvis and the ureter are also 
included in the figure. The crude incidence of UTUC in the 
whole time period was 3.17:100.000, increasing from 2.54 
to 3.98 from the first to last 5 year periods. The estimated 
annual increase was 0.09 (CI 0.07–0.12), p < 0.001) result-
ing in an EAPC of 3%. The ASR adjusted to the European 
standard population was 3.88 for the whole period, increas-
ing from 3.21 to 4.70. The increase per year was 0.10 (CI 
0.06–0.13, p < 0.001) with an EAPC of 2.5%. The ASR 
of UTUC in the kidney pelvis increased from 1.77 to 2.88 
from first period to last, p < 0.001. For ureteral tumours 
the increase was from 1.44 to 1.82 during the same period, 
p < 0.001. The proportion of tumours in the renal pelvis 
compared to all UTUC increased non-significantly from 
55.6 to 61.2%, p = 0.06. The ASRs adjusted to other standard 
populations are presented in Supplementary Table 1 and 2.
Analyses showed that UTUC incidence increased in all 
age-spans above 60 years age, see supplementary Fig. 2. 
There was no increase over time in new yearly UTUC cases 
among patients under the age of 60, but comparing first 
5-year periods with the last the increase was apparent and 
significant for each decade from 60 to 69 years (131–254 
cases, 94% increase) 70–79 years (243–399 cases, 64% 
increase) and 80 + years (121–303 cases, 150% increase), 
all p < 0.001.
Patient demographics, tumour features and developments 
over time are shown in Table 2. The table also includes com-
parisons between UTUC and other urothelial cancers and 
RCC.
Mean (median, IQR) age of all UTUC patients during the 
whole period was 72.8 (73.8, 65.8–79.8) years. Patient mean 
age at diagnosis increased from 71.8 to 73.9 from the first 
to last 5 year periods, p < 0.001. No gender-specific changes 
over time were observed.
No statistically significant stage migration over time was 
observed. The proportion of invasive tumours decreased 
non-significantly from 50.0 to 41.7% compared to non-
invasive tumours (p = 0.07). Invasive tumours were equally 
frequent irrespective of gender or age. Similarly, analyses 
were performed regarding regional node or distant metas-
tases, but no differences over time were observed for the 
entire cohort or stratified by age or gender. The proportion 
of cases where invasiveness was not assessable increased 
over time, corresponding to an increase in cases verified by 
biopsy only, and a decrease in radical surgery.
Fig. 1  Demonstrates the 5-years average UTUC incidence per 
100.000 and changes over time. Illustrates the crude rates (blue) and 
the age-standardized incidence rates adjusted to the European stand-
ard population, 2013 version, green). Includes the incidence rates of 
UTUC in the kidney pelvis (red) and the ureter (orange)
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During the whole study period, 75.2% of the patients 
were treated with radical surgery. The absolute number of 
patients treated with radical surgery increased by 55.5% dur-
ing the study period, but since number of cases increased by 
81.4%, there was a net decline in the proportion of patients 
treated with radical surgery over time from 82.6 to 70.8% 
(p < 0.001). The proportion of patients with a biopsy verified 
diagnosis without following radical surgery increased cor-
respondingly from 10.8 to 23.7% in the same period.
Regarding the oldest patients (> 80 years of age) fewer 
patients (59.3%) were treated with radical surgery, decreas-
ing from 64.5 to 55.6% in the study period. More of these 
patients were diagnosed with biopsy without following radi-
cal treatment, increasing from 18.2 to 31.2% in the study 
period. Among these oldest patients, it was also more com-
mon that the diagnosis was not verified with a histopatho-
logical specimen, (16.0% vs 2.8% for patients < 80 years 
age), stable during the study period.
The 5, 10 and 15-years OS were 48.3%, 33.2% and 22.5%, 
respectively. The 5, 10 and 15-years CSS were 61.4%, 56.1% 
and 51.1%, respectively (Fig. 2). All the following survival 
data are given as 5-years CSS. Patients treated with radi-
cal surgery had significantly higher survival compared to 
patients not treated with radical surgery (67.2% vs 41.6%, 
p < 0.001), respectively. The patients with non-invasive 
Table 2  Changes over time regarding patient demographics, tumour features and new cases of upper tract urothelial carcinoma compared to 
other urothelial cancers and renal cell carcinoma
a Increase in percent from first to last 5-year periods
b p values based on regression analyses assessing yearly changes
c Chi-square comparing invasive with non-invasive
Variable All 1999–2003 2004–2008 2009–2013 2014–2018 %a pb
Mean age (years) 72.8 71.8 72.0 72.6 73.9  < 0.001
Gender %
 Female 37 41.1 32.3 39.3 36.1 0.3
 Male 63 58.9 67.7 60.7 63.9
Location
 Kidney pelvis 58.5 55.6 56.1 59.1 61.2 0.06
 Ureter 41.5 44.4 43.9 40.9 38.8
Tumour stage %
 Invasive (T2–T4) 46.9 50.0 47.7 50.7 41.7 0.07c
 Non-invasive (Ta–T1) 41.4 42.5 42.7 39.1 41.8
 Invasiveness not assessable (Tx) 11.7 7.5 9.5 10.1 16.5  < 0.001
 Regional node metastases 5.2 4.7 5.4 6.6 4.2 0.9
 Distant metastases 9.6 9.9 10.4 9.8 8.8 0.5
Upper tract urothelial carcinoma (n) 3096 574 681 800 1041 81  < 0.001
 Bladder cancer 24,467 5251 5910 6181 7125 36  < 0.001
 Urethral cancer 287 61 74 54 98 61 0.2
 Total Urothelial cancer 27,850 5886 6665 7035 8264 40  < 0.001
 % Upper tract urothelial carcinoma 11.1 9.8 10.2 11.4 12.6 29  < 0.001
Renal tumours (n)
 Urothelial carcinoma kidney pelvis 1811 319 382 473 637 100  < 0.001
 Renal cell carcinoma 13,619 2501 3103 3711 4304 72  < 0.001
 Total 15,430 2820 3485 4184 4941 75  < 0.001
 %Upper tract urothelial carcinoma 11.7 11.3 11.0 11.3 12.9 14 0.04
Fig. 2  Shows the estimated overall- and cancer-specific survival 
curves of the entire cohort using the Kaplan–Meier method. The 5, 
10 and 15-years OS were 48.3%, 33.2% and 22.5%, respectively. The 
5, 10 and 15-years CSS were 61.4%, 56.1% and 51.1%, respectively
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tumours had higher survival compared to patients with 
invasive UTUC (79.4% vs 49.8%, p < 0.001). Survival dete-
riorated with increasing age, patients < 70 years 68.1%, 
70–80 age 63.5% and > 80 years of age 46.7%, respectively, 
p < 0.001. No differences in survival stratified by gender or 
tumour location were detected.
Both OS and CSS improved over time, comparing the last 
decade with the first (5-year OS 44.0% vs 53.2%, p ≤ 0.001 
and 5-year CSS 57.4% vs 65.4%, p ≤ 0.001), respectively. 
This improvement over time was present for all sub-groups 
irrespective of age, gender, type of treatment and tumour 
location.
Discussion
If the commonly quoted incidence rate of 1–2:100.000 
from the American Cancer society serves as a reference, the 
ASR of 4.7:100.000 in the present study was higher than 
expected, and to our knowledge the highest incidence rate 
published based on a population outside endemic areas. 
There was an estimated annual percentage change in the 
incidence rate of 2.5%, corresponding to an 81% increase in 
new cases comparing first with last 5-year periods.
The reason for the demonstrated increase is not clear. One 
possible explanation could be that symptoms i.e. haema-
turia are more vigorously examined in older patients now 
than before. An improved access to high-quality computed 
tomography and better equipment for flexible ureteroscopy 
could add to this effect. This could lead to a higher detection 
rate of UTUC and increased age at diagnosis. Indeed, we 
have seen a considerable increase in biopsy verified cases 
without following radical surgeries. This increase is even 
more evident among patients > 80 years of age, the same age 
group that showed the greatest increase in new yearly cases. 
These data indicate that at least some of the demonstrated 
increase in incidence could be due to increased diagnostics, 
especially among the oldest patients.
The decrease in radical treatments could be caused by an 
increased use of endoscopic treatment. Unfortunately, the 
data from the NCR does not include data on endoscopic 
treatment. However, an increasing number of publications 
with relatively larger cohorts on the use of endoscopic 
treatment could indicate an increased use of this treatment 
modality [9, 10]. Another reason could be that observation 
was chosen over radical surgery due to high age, poor per-
formance status or favourable tumour characteristics. Data 
on performance status are not available in the present data-
set, but a considerable and increasing proportion of patients 
were at a high age where larger surgeries might not be 
recommended.
In spite of these possible reasons for the described 
increase, it seems likely that there is a true increase in 
UTUC in Norway for the last 20 years, and not just an 
increased detection rate. The known risk factors for UTUC 
include smoking [11, 12], excessive alcohol consump-
tion and exposure to aristolochic acid [13]. The dataset 
obtained from the NCR does not contain information about 
smoking, alcohol use or exposure to possible carcinogens. 
An evaluation about the potential effect of changing expo-
sure to known risk factors is for this reason not possible 
without obtaining further data and was beyond the scope 
of this paper. Further studies to clarify the reasons for the 
described increase are needed.
In the present cohort, we found an all-cohort 5-years 
CSS and OS of 61.4% and 48.3%, respectively. Other pop-
ulation-based publications on UTUC which include sur-
vival data have demonstrated similar survival outcomes. 
Raman et  al. presented a 5-years OS of ~ 50% in their 
cohort [3], while Eylert et al. reported a falling 5-years 
relative survival rate from 60 to 48% during their study 
period [14]. Woodford et al. reported a 5-years overall 
survival rate of 32% [5]. Compared to these more historic 
cohorts, the present study demonstrated comparable or 
favourable survival outcomes. A moderate improvement 
in survival over time was observed. The reason for this 
improvement is unclear. Increased use of adjuvant thera-
pies for UTUC including both perioperative chemotherapy 
[15, 16] and the introduction of immunotherapies [17] 
could possibly explain some of the demonstrated improved 
survival in the present cohort. Unfortunately, the data at 
NCR is very limited regarding the use of adjuvant treat-
ment, and no firm conclusions can be drawn.
As UTUC is a potentially lethal disease if left untreated, 
one would expect that earlier detection and treatment 
could result in improved survival. In the present cohort, 
we found an increased use of biopsies without following 
radical treatment. As stated earlier, the present data set is 
not complete regarding tumour stage, but a non-signifi-
cant decline in the proportion of invasive tumours was 
observed. It is possible that more cases are detected at an 
earlier stage presently compared to previously, resulting 
in improved survival.
Our findings could have several possible implications. 
One implication could be an increased focus on UTUC, 
simply because more patients than expected would be 
affected by the disease. Another implication could be 
enrolment into studies. There are many unanswered ques-
tions regarding the diagnostic work-up and treatment of 
UTUC, such as the optimal use of perioperative chemo-
therapy or the use of lymph node dissection at the time of 
RNU. A higher incidence would result in quicker enrol-
ment into much needed studies on the topic, and make 
studies with adequate patient numbers more feasible to 
conduct.
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Strengths and weaknesses
The present publication is based on national data from 
Norway, analysing 3096 UTUC cases during 20 years, a 
sufficient number of cases to make reliable conclusions 
about a relatively rare disease. The NCR is nationwide and 
has since 1953 kept a complete registry of all new cases of 
malignant neoplasms. It has documented a high degree of 
data quality including key aspects such as completeness, 
comparability and validity [18]. The data material was 
quality assured, based on clinical and pathology reports, 
and statistical advice was sought to make sure the methods 
used for incidence measurements, population adjustment 
and changes over time were performed in the correct way.
This study is not without limitations. One weakness of 
the study is that the analyses were based on registry data 
partly based on clinical reports made from a wide range 
of clinicians, with an inherent risk of coding errors. More 
specifically the dataset is limited by a lack of accurate 
data regarding tumour stage and specific data on treatment 
i.e. the use of endoscopic treatment. The data also has 
limitations regarding the registration of CIS, prior blad-
der cancer, race and the use of adjuvant treatments. As the 
present study is a population-based registry study with the 
described limitations, the ability to draw firm conclusions 
about the causality concerning our findings is limited. 
Further studies to explore further possible reasons for the 
increased incidence, changing demographics and improved 
survival are warranted.
Conclusion
The incidence of UTUC was higher than previously 
reported, and increasing. UTUC incidence in Norway during 
2014–2018 was 4.7:100.000. UTUC currently constitutes 
close to 13% of all urothelial cancers, and urothelial cancers 
of the renal pelvis currently constitute close to 13% of all 
malignant renal tumours. The increase was not accompanied 
by stage migration, but survival moderately improved. The 
patients are older at the time of diagnosis currently com-
pared to earlier, but no other changes in patient demograph-
ics were detected.
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